JP2015513919A5 - - Google Patents

Info

Publication number

JP2015513919A5

JP2015513919A5 JP2015505732A JP2015505732A JP2015513919A5 JP 2015513919 A5 JP2015513919 A5 JP 2015513919A5 JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015513919 A5 JP2015513919 A5 JP 2015513919A5

Authority

JP

Japan

Prior art keywords

pancreatic cancer

cancer cell

aptamer

molecules

seq

Prior art date

2013-03-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 25
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 25
• 201000002528 pancreatic cancer Diseases 0.000 claims 25
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 25
• 210000004027 cell Anatomy 0.000 claims 18
• 108091023037 Aptamer Proteins 0.000 claims 14
• 229940124597 therapeutic agent Drugs 0.000 claims 11
• 239000003814 drug Substances 0.000 claims 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
• 239000000032 diagnostic agent Substances 0.000 claims 3
• 229940039227 diagnostic agent Drugs 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 208000009164 Islet Cell Adenoma Diseases 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 108091027967 Small hairpin RNA Proteins 0.000 claims 2
• 108020004459 Small interfering RNA Proteins 0.000 claims 2
• 239000012830 cancer therapeutic Substances 0.000 claims 2
• 201000000052 gastrinoma Diseases 0.000 claims 2
• 108020004999 messenger RNA Proteins 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 108091070501 miRNA Proteins 0.000 claims 2
• 239000002679 microRNA Substances 0.000 claims 2
• 239000002773 nucleotide Substances 0.000 claims 2
• 125000003729 nucleotide group Chemical group 0.000 claims 2
• 239000004055 small Interfering RNA Substances 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
• 206010018404 Glucagonoma Diseases 0.000 claims 1
• 102000018697 Membrane Proteins Human genes 0.000 claims 1
• 108010052285 Membrane Proteins Proteins 0.000 claims 1
• 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 claims 1
• 206010041329 Somatostatinoma Diseases 0.000 claims 1
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
• 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
• 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
• 208000006336 acinar cell carcinoma Diseases 0.000 claims 1
• 208000009956 adenocarcinoma Diseases 0.000 claims 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000000975 dye Substances 0.000 claims 1
• 239000003623 enhancer Substances 0.000 claims 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 206010022498 insulinoma Diseases 0.000 claims 1
• 230000003834 intracellular effect Effects 0.000 claims 1
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
• 201000002529 islet cell tumor Diseases 0.000 claims 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims 1
• 208000022669 mucinous neoplasm Diseases 0.000 claims 1
• 239000002105 nanoparticle Substances 0.000 claims 1
• 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 1
• 208000002820 pancreatoblastoma Diseases 0.000 claims 1
• 239000012857 radioactive material Substances 0.000 claims 1
• 208000011581 secondary neoplasm Diseases 0.000 claims 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 230000005945 translocation Effects 0.000 claims 1